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Introduction
Since the outbreak of the novel coronavirus in Decem-
ber 2019 in Wuhan, China, SARS-CoV-2 or COVID-19 has 
spread worldwide at an unexpected rate, becoming a pan-
demic major concern1–3. It is an infectious disease caused 
by a newly discovered single-stranded RNA coronavirus2. 
Although most human coronavirus infections are mild, 
former epidemics of the two beta coronaviruses, severe 
acute respiratory syndrome coronavirus (SARS-CoV) and 
Middle East respiratory syndrome coronavirus (MERS-
CoV) have caused more than 10 000 cumulative cases in 
the past two decades, with mortality rates of 10% for 
SARS-CoV and 37% for MERS-CoV2,3. SARS-CoV-2 rep-
resents a challenge for both clinicians and scientists with 
by now almost 47 million confirmed cases and more than 
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A B S T R A C T
Given high risk of infection-related mortality due to impaired immunity, elderly patients are at increased risk with 
COVID-19. In its diagnostic procedure clinical laboratory medicine has a pivotal role. The aim of this study was to in-
vestigate clinical and laboratory specificities in Croatian population of nursing home residents affected by coronavirus. 
One hundred and six residents of nursing homes that were hospitalized due to COVID-19 infection, were included in this 
retrospective study. Clinical and laboratory findings at three time points were extracted from medical records. There were 
86 females and 20 males, with median of age 84 (min-max: 47–97) years. Patients were divided into three groups: Survi-
vors (S), patients who are still alive (N=65), In-Hospital Non-Survivors (IHNS), patients who died from coronavirus 
during hospitalization (N=31) and Out-of-Hospital Non-Survivors (OHNS), patients who recovered from infection but 
died during the period of three months of the follow-up (N=10). We have established differences between these three groups 
in laboratory findings (p<0.05). At the admission, survivors had lower values of lactate dehydrogenase, aspartate trans-
aminase, sedimentation ratio, ferritin and C-reactive protein, OHNS were in the middle, and IHNS had the highest 
values. Leukocytes and absolute lymphocyte count were greater in OHNS group, and same between survivors and IHNS. 
After 7 days, we noticed increase in leukocyte and neutrophils count among IHNS. Assessing of complete blood count, 
differential blood count, reactants of acute infection and combination of their ratios might predict worse outcome in nurs-
ing home residents due to coronavirus infection. 
Keywords: COVID-19, coronavirus, nursing care home, elderly, mortality, laboratory medicine 
1,205,000 deaths in 216 countries, areas or territories 
worldwide and no appeasement is in sight4. 
The first detected case of coronavirus in Croatia was 
imported on February 25th in the capital city of Zagreb, 
and in Split-Dalmatia County, main region of Dalmatia 
almost a month later, on 17th March 2020. Despite the fact 
that the age range of patients has dropped, older patients 
are still under the high risk. The main problems are the 
lack of continuous knowledge, asymptomatic spreading of 
the virus and unpredictable clinical course. According to 
data from the literature, older age, male sex, and chronic 
medical conditions, such as diabetes, hypertension, obe-
sity and heart diseases, might be risk factors associated 
with worse outcomes5. Therefore, the nursing home sector 
has recently seen a disproportionately high number of 
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deaths6. According to experts, this was connected with the 
frailty and vulnerability of older people living in nursing 
care homes and in a part a consequence of the failure of 
including them in the systematic planning of a response 
to COVID-19 disease6. Despite the fact of aging population 
– 617 million people are aged 65 and over, some countries, 
including Croatia, still do not have developed special ge-
riatrics network4. Little is known about risk factors as-
sociated with COVID-19 in European population. The aim 
of this study was to elucidate risk and prognostic factors 
as well as clinical characteristics among nursing care 
homes residents that were hospitalized in tertiary clinical 
centre due to COVID-19 infection. 
Materials and Methods
Subjects
At the beginning of COVID-19 epidemic in Europe, 
University Hospital Centre of Split, the second biggest 
tertiary medical institution in Croatia was rearranged to 
COVID Hospital, i.e. Respiratory Intensive Centre, re-
gional coronavirus centre for four counties in the region of 
south Croatia. All adult (older ≥ 18 years) COVID-19 pos-
itive nursing care home residents who were admitted to 
the hospital in the period of March to May 2020 from five 
different senior homes, were included in this retrospective 
study. Positive oropharyngeal and nasopharyngeal SARS-
CoV2 swabs (COVID 19 RT-PCR test, Cobas 480, Roche, 
kit LightMix®Modular SARS and Wuhan CoVE-gene and 
RdRP-gene) were indication for hospitalization regardless 
of clinical presentation. Criteria for discharge from the 
hospital were: two consecutive negative SARS-CoV2 
swabs within 48 hours, no symptoms, at least 7 days 
elapsed since the beginning of the disease and last 3 days 
without fever.
Methods
Relevant anamnestic data, description of clinical pre-
sentation and standard laboratory parameters, performed 
in routine analyses, were reviewed from the electronical 
medical records. This included complete blood count and 
absolute count of differential blood count, biochemical pa-
rameters of kidney, heart and liver function, markers of 
acute infection, coagulogram and urine analysis. Accord-
ing to complete blood count several ratios were calculated: 
neutrophils to lymphocyte (N/L); neutrophil/lymphocyte 
× platelet (N/LP) and platelet, neutrophil, and lymphocyte 
ratio (PNLR). All tests were measured by standard labo-
ratory methods.
Three time points of laboratory sampling were chosen 
for this research: at the admission, after 7 days respecting 
pathophysiological peak in viral load and after relief of 
symptoms, i.e. at the time of discharge or death7. The pri-
mary endpoint was in-hospital mortality, and secondary 
endpoint was out of hospital mortality in the period of 
three months of the follow-up. Study was conducted ac-
cording to Helsinki declaration and was approved by local 
ethics committee. No additional blood sampling or any 
other procedure was needed for this study, so informed 
consent was not obtained from each patient. 
Statistical analysis
Statistical significance was set at p < 0.05, and all con-
fidence intervals (CI) were at the 95 % level. We performed 
descriptive statistics including means ± standard devia-
tions and medians and interquartile, respectively. Analy-
sis of statistical significance of differences in several nu-
merical variables was performed with the Kruskal-Wallis 
test and of differences between the two groups with the 
Mann-Whitney and Dunn test. Other tests used in this 
research were χ2 test and Fisher's exact test. To compare 
the risk of in-hospital death of patients with COVID-19 we 
performed multiple linear regression and logistic regres-
sion models. Receiver operating characteristic (ROC) 
curves were performed to calculate cut-off values signifi-
cant for in – hospital mortality. Statistical analysis was 
performed using National Council for the Social Studies 
(NCSS) 2020 software.
Results
One hundred and six COVID 19 positive nursing care 
home residents were hospitalized in regional COVID hos-
pital in south Croatia and all of them were later included 
in this study. There were 86 (81.13%) females and 20 
(18.87%) males, with median of age 84 (min-max: 47–97) 
years. Patients were divided into three groups: Survivors 
(S), patients who are still alive, In-Hospital Non-Survivors 
(IHNS), patients who died during hospitalization and Out-
of-Hospital Non-Survivors (OHNS), patients who were 
discharged from hospital, but died during the period of 
three months of the follow-up. Table 1 shows demographic 
characteristics of all participants. 
Patients did not differ by age, but there was a signifi-
cant difference in sex distribution. Males were represent-
ed equally to females in OHNS group, in contrast to S and 
INHS groups, where women predominated. Patients from 
senior homes were characterized with high prevalence of 
comorbid diagnoses of arterial hypertension (63.21%), 
diabetes (29.25%), cardiovascular diseases (coronary ar-
tery disease or heart failure) (36.79%) and neurological 
complications including dementia and recent cerebrovas-
cular incidents with residual neurological deficits (48.11%). 
Out of hospital non-survivors more often suffered from 
arterial hypertension and dementia, while diabetes and 
cardiovascular comorbidities were more common in in-
hospital non-survivors group. Clinical presentation of CO-
VID 19 infection was diverse, but mostly consisted of fever, 
dyspnoea and non-productive cough. Detailed view of 
various symptoms is presented in Table 2. Thirty patients 
did not have any symptom of infection on the admission, 
but most of them developed/continued with fever or dys-
pnoea during hospitalization. Three patients (2.83%) re-
mained asymptomatic all the time. Radiological findings 
proven by X-ray and MSCT of thorax differed between 
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TABLE 1















Age* 84 (11) 84 (7) 86 (14) 82 (11.25) / 0.214**
Sex 86F, 20M 57F, 8M 24F, 7M 5M, 5F 18.536 0.005
BMI: 
Underweight
21(19.81) 8 (12.30) 7 (22.58) 6 (60) 17.918 0.009
Normal weight 67 (63.21) 54 (83.08) 10 (32.26) 3 (30)
Overweight + obesity 18 (16.98) 3 (4.62) 14 (45.16) 1 (10)
Diabetes mellitus type 2 31 (29.25) 16 (24.62) 12 (38.71) 3 (30) 13.308 0.038
Arterial hypertension 67 (63.21) 39 (60) 20 (64.52) 8 (80) 12.975 0.043
Hyperlipidaemia 2 (1.89) 1 (1.54) 1 (3.23) 0 (0) 12.011 0.062
CVD 39 (36.79) 18 (27.69) 16 (51.61) 5 (50) 17.290 0.009
COPD 9 (8.49) 4 (6.15) 4 (12.90) 1 (10) 12.545 0.051
CKD 6 (5.66) 1 (1.54) 3 (9.68) 2 (20) 17.397 0.008
Active malignant disease 4 (3.77) 3 (4.62) 1 (3.23) 0 (0) 12.251 0.057
Neurological disease 51 (48.11) 28 (43.07) 16 (51.61) 7 (70) 14.113 0.028
*median (IQR); **Kruskal Wallis test; BMI – body mass index, CVD – cardiovascular disease, COPD – chronic obstructive pulmonary 
disease, CKD – chronic kidney disease
TABLE 2














Chest pain 4 (3.77) 2 (3.08) 1 (3.23) 1 (10) 12.201 0.058
Abdominal pain 1 (0.94) 1 (1.58) 0 (0) 0 (0) 12.320 0.055
Diarrhoea 6 (5.66) 4 (6.15) 1 (3.23) 1 (10) 13.055 0.160
Vomiting and nausea 6 (5.66) 3 (4.62) 3 (9.68) 0 (0) 13.424 0.037
Loss of sense of smell and taste 7 (6.60) 6 (9.23) 1 (3.23) 0 (0) 15.976 0.192
Sore throat 5 (4.72) 5 (7.69) 0 (0) 0 (0) 16.382 0.174
Weakness 14 (13.21) 8 (12.31) 4 (12.90) 2 (20) 11.742 0.068
Arthralgia and myalgia 5 (4.72) 2 (3.08) 2 (6.45) 1 (10) 12.441 0.053
Headache 3 (2.83) 2 (3.08) 0 (0) 1 (10) 14.275 0.027
Dyspnoea 25 (23.58) 12 (18.46) 9 (29.03) 4 (40) 14.148 0.028
Cough 35 (33.02) 25 (38.46) 7 (22.58) 3 (30) 13.859 0.031
Fever 42 (39.62) 23 (35.38) 14 (45.16) 5 (50) 12,663 0.049
Respiratory insufficiency depen-
dent on mechanical ventilation 15 (14.15) 1 (1.54) 14 (45.16) 0 (0) 44.750 0.000
Radiological findings:
Normal
53 (50) 38 (58.46) 10 (32.26) 5 (50)
21.410 0.045Unilateral pneumonia 21 (19.81) 14 (21.54) 6 (19.35) 1 (10)
Bilateral pneumonia 30 (28.30) 12 (18.46) 14 (45.16) 4 (40)
Ground glass opacity 2 (1.87) 1 (1.54) 1 (3.23) 0 (0)
Average days of hospitalization* 23.5±11.79 25.08±8.97 18.48±14.81 28.8±13.52 15.153 0.001
*mean ± standard deviation
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each group (p=0.045), ranging from normal, through uni-
lateral or bilateral inhomogeneous shading to typical 
ground glass opacity with crazy paving appearance, air 
space consolidation, bronchovascular thickening in the le-
sion and traction bronchiectasis (Table 2). Average days of 
hospitalization were 23.5±11.79. In post-hoc analysis pa-
tients who survived differed from those who died during 
hospitalisation (p<0.001, Z=–3.667) in duration of treat-
ment, but not from those who died during the follow-up 
period (p=0.634, Z=0.476). The two groups of non-survi-
vors differed in days of hospitalization (p=0.007, Z=2.675) 
(Table 2). Oxygen supplementation through nasal cannu-
las was needed for 28 patients (12, 12, 4, respectively) 
(p=0.010, χ2=16.713) and mechanical ventilation for 15 
patients (p=0.000, χ2=44.750) predominately (93.33%) in 
in-hospital non-survivor group. Serial laboratory tests 
were performed for each patient. 
At the admission IHNS had higher values of median 
(IQR) of lactate dehydrogenase than S (p=0.005) and 
OHNS (p=0.047), 273 (182) U/L and 189 (83.5) U/L and 
173.5 (94.75) U/L respectively, RR: 25-241 U/L). Median 
(IQR) of aspartate transaminase was higher in both IHNS 
(37 (25) U/L) and OHNS (32 (28.25) U/L) than in S group 
(25 (16) U/L) (p=0.009 and p=0.046, respectively, RR: 
11–38 U/L). Fibrinogen level (RR: 1.8 – 3.5 g/L) differed 
only between non – survivors and survivors (6.2 (2.5) g/L) 
p=0.049 and p=0.036, respectively, but not between in and 
out of hospital non – survivors, p=1.000, (3.9 (0.6) and 4.05 
(3.85) g/L). Sedimentation ratio (RR: 4–24 mm/3.6ks) dif-
fered only between survivors and IHNS (p=0.042), 52.5 
(46.75) mm/3.6ks and 91 (32.25) mm/3.6ks, respectively. 
At the admission IHNS had higher values of median (IQR) 
of ferritin than S (p<0.001) and OHNS (p<0.001), 2325 
(626) ng/ml, 246 (479.5) and 82 (203) respectively, RR: 
10–120 ng/ml).
In Table 3 only medians of those laboratory parameters 
that significantly differed between groups in at least two 
or all three analyses are presented. In post hoc analysis 
subgroups of patients were correlated to each other. Be-
tween Survivors and In Hospital Non-Survivors group, 
there were statistically significant differences in all pa-
rameters presented in Table 3 (all p<0.05) except for hae-
moglobin 2 levels. 
Table 4 shows medians (IQR) of differential blood count 
in COVID-19 positive patients. Parameters that differed 
between survivors and non-survivors were higher leuko-
cytes with absolute neutrophils and lymphocyte counts in 
TABLE 3
MEDIANS OF LABORATORY FINDINGS IN COVID 19 POSITIVE PATIENTS IN TRIPLE CONSECUTIVELY SAMPLING: 










Laboratory measurement 1. 2. 3. 1. 2. 3. 1. 2. 3. p1 p2 p3
Haematology
Leukocytes (1e9/L) 5.9 6.3 6.4 5.9 9.5 12.7 7.1 6.5 10.1 0.311 0.001 <0.001
Erythrocytes (1e12/L) 4.42 4.3 4.23 3.9 3.8 3 4.51 4.4 3.8 0.002 0.013 0.003
Haemoglobin (g/L) 132 128 124 122.5 119 93 134.5 132.5 117.5 0.025 0.045 0.004
RDW (%) 14.4 14.3 14.7 15.2 15.1 15.8 14.4 14.1 14.1 0.047 0.004 0.003
Neutrophils (1e9/L) 3.5 4.2 4 3.7 7.4 11 4.6 4.1 7.6 0.185 <0.001 <0.001
Lymphocytes (1e9/L) 1.3 1.9 1.4 0.9 0.9 0.8 1.5 1.3 1.3 0.006 0.042 0.002
Biochemistry
Urea (mmol/L) 7.1 7.5 6.7 11.2 15.9 14.1 10.3 10.5 5.7 0.029 <0.001 <0.001
Uric acid (µmol/L) 320 319 289 481 617 467 427 618 156 0.192 0.013 0.034
Albumins (g/L) 34 32 31 30.5 26 21 35 36 29 0.049 0.027 0.043
CRP (mg/L) 19.4 23.1 14.15 72.9 105.2 118.5 42.6 62.4 65.2 <0.001 <0.001 <0.001
Procalcitonin (ng/mL) 0.1 0.09 0.08 0.2 0.17 0.6 0.2 NA 0.1 0.138 0.002 <0.001
Hs-Troponin T (ng/L) 21.4 28.9 24.7 47.8 62 176.4 38.7 NA 55.6 0.038 0.028 0.346
Ratios
N/LP 1.11 1.29 0.87 2.2 3.7 3.74 1.31 1.1 1.5 0.011 0.005 0.001
N/L 2.8 3.71 2.93 4.3 8.3 6.36 3 2.75 7.1 0.042 0.001 0.000
PNLR 540.4 788.2 932.5 765.7 1902.5 1632.1 744.5 702.1 2566.3 0.237 0.007 0.001
L/CRP 0.05 0.05 0.09 0.01 0.01 0.01 0.05 0.02 0.02 0.002 0.026 0.002
NA − not applicable, N − neutrophils, L − lymphocytes, P − Platelets, CRP − C reactive protein, RDW − Red Cell Distribution Width
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those who died. Eosinophils count was the highest in out of 
hospital non-survivors group in the third sampling 
(p=0.049) but it did not differ in previous two samplings. 
When patients were divided into two groups – those with 
and without bacterial co-infection, they did not differ in any 
finding of differential blood counts in the first two sam-
plings (all p>0.05), only in leukocytes (p=0.003) and neu-
trophils absolute count in the third sampling (p=0.001) 
which both were higher in the group with bacterial super-
infection. 
In the further analysis prognosis of in-hospital lethal 
outcome was performed using different regression models. 
The results confirmed that basic laboratory findings includ-
ing higher leukocytes, neutrophils, C-reactive protein and 
several ratios: neutrophils to lymphocyte (N/L), neutrophil/
lymphocyte × platelet (N/LP) and platelet, neutrophil, and 
lymphocyte ratio (PNLR) were connected with poor out-
come in elderly COVID-19 positive patients (Table 5).
In-hospital mortality was related to older age (p<0.001, 
95%CI: 0.002–0.004) and chronic comorbidities such as 
diabetes [OR] 0.245, p=0.043, 95%CI 0.003–15.801, hy-
perlipidaemia (p=0.045, [OR] 5.110, 95%CI: 1.881–13.886), 
cardiovascular diseases (p=0.013, [OR] 2.412, 95%CI: 
1.022–5.691), arterial hypertension (p=0.043, [OR] 2.667, 
95%CI: 2.362–2.365) and neurological comorbidities 
(p=0.028, [OR] 2.467, 95%CI: 2.465–2.468). Angiotensin 
converting enzyme inhibitors use, which was recorded in 
29 patients, was not associated with lethal outcome 
(p=0.904). Addiction to mechanical ventilation was sig-
nificantly connected with lethal outcome (p<0.001, [OR] 
53.449, 95%CI: 6.501–439.477). Receiver operating char-
acteristic (ROC) curve with area under curve (AUC) were 
TABLE 4











Median IQR Median IQR Median IQR Median IQR p
Leu1 6 2.95 5.9 2.75 5.9 6.48 7.1 1.25 NS
Ne1 3.6 2.96 3.465 2.53 3.67 5.49 4.59 1.77 NS
Ly1 1.26 0.81 1.32 0.82 0.94 0.60 1.53 0.79 0.006
Mo1 0.45 0.26 0.45 0.25 0.42 0.35 0.51 0.33 NS
Eo1 0.04 0.07 0.05 0.08 0.02 0.05 0.06 0.16 NS
Ba1 0.02 0.02 0.02 0.02 0.02 0.02 0.03 0.02 NS
Er1 4.35 0.83 4.42 0.87 3.86 0.94 4.51 0.29 0.002
Pl1 218 122 221 120.5 190 165 229 81 NS
Leu2 6.8 3.7 6.3 3.5 9.5 7.7 6.45 3.35 0.001
Ne2 4.75 3.81 4.24 2.96 7.42 7.47 4.14 2.68 <0.001
Ly2 1.18 0.69 1.19 0.77 0.93 0.67 1.31 0.62 0.049
Mo2 0.51 0.32 0.48 0.32 0.57 0.25 0.55 0.56 NS
Eo2 0.07 0.13 0.08 0.13 0.03 0.12 0.06 0.15 NS
Ba2 0.02 0.01 0.02 0.02 0.02 0.02 0.03 0.02 NS
Er2 4.2 0.9 4.3 0.77 3.82 1.39 4.39 0.63 0.013
Pl2 261.5 151,8 269 145 255 125 262.5 151.25 NS
Leu3 7.1 5.8 6.35 2.85 12.7 10.7 10.05 1.6 <0.001
Ne3 4.88 5.1 4 2.44 11.02 10.59 7.65 1.69 <0.001
Ly3 1.29 0.7 1.4 0.58 0.84 0.72 1.31 0.57 0.002
Mo3 0.52 0.29 0.5 0.25 0.48 0.63 0.67 0.54 NS
Eo3 0.12 0.16 0.13 0.11 0.08 0.19 0.24 0.26 0.049
Ba3 0.03 0.03 0.03 0.02 0.04 0.04 0.04 0.04 NS
Er3 4.09 1.18 4.23 1.07 3.03 3.12 3.84 0.67 0.003
Pl3 297 162 297 121.75 238 176 382 199.75 0.038
Leu − leukocytes, Ne − neutrophils, Ly − lymphocytes, Mo − monocytes, Ba − basophils, Eo − eosinophils, Er − erythrocytes, 
Pl − platelets
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used to establish cut-off values of complete blood count to 
differentiate patients who recovered or died in the hospital 
of coronavirus. Combination of higher neutrophils and 
leukocytes count accompanied with ratios showed specific-
ity in predicting lethal outcome (Table 6). At the admis-
sion, N/L ≥ 3.32, N/LP ≥ 1.78 and PNLR ≥ 621.5 were 
associated with higher in-hospital mortality ratio. After 7 
days, i.e. in the peak of viremia those ratios increased to 
4.14, 2.65 and 1600.24, respectively.
Discussion
In a short period of time, SARS-CoV2 infection has 
become the world's leading health problem. Combining as-
sessment of imaging diagnostic methods with clinical and 
laboratory findings could facilitate early diagnosis of CO-
VID-19 complications. In this study we have proven dif-
ferences in clinical and laboratory findings, outcomes and 
risk factors for death in European COVID-19 nursing 
home residents among survivors and both in– and out of 
hospital non-survivors. Residents at nursing care homes 
represent a specific elderly population, generally charac-
terized by higher comorbidity than community adults and 
higher vulnerability to infections8. There is a higher like-
lihood for spread of virus because of closer contacts be-
tween them in view of aerosol transmission as main path-
way of infection, insufficient isolation opportunities, 
inadequate hygiene, and cognitive impairment and im-
mune-supressed states8. All of our participants had one or 
more comorbidities and nationwide studies from China 
confirmed that COVID-19 positive patients with any co-
morbidity yielded poorer clinical outcomes than those 
without. The risk was higher when greater number of co-
morbidities was present9. Hypertension, diabetes, COPD 
and malignancy correlated with poorer clinical outcomes 
in accordance with our data9. Furthermore, more than 
60% of non-survivors were either underweight or over-
weight. Patients, who were obese, mostly died during hos-
pitalization, and those with lower body weight after dis-
charge. In clinical practice, only 3 to 5% of hospitalized 
population is diagnosed with malnutrition, although real 
numbers are even 10 times higher10. Bencivenga et al. have 
proposed that correction of nutritional deficits may at-
tenuate the age-dependent alterations of the innate and 
adaptive immune system which participate in the in-
TABLE 5
























Leukocytes 0.060 0.036 0.004 0.114 0.064 <0.001 0.032 0.096 0.059 <0.001 0.036 0.084
Erythrocytes –0.489 0.001 –0.761 –0.217 –0.318 0.009 –0.555 –0.081 –0.439 <0.001 –0.669 –0.209
Haemoglobin –0.012 0.013 –0.022 –0.003 NS –0.015 0.001 –0.023 –0.001
RDW 0.157 0.005 0.048 0.266 0.163 0.005 0.049 0.276 0.156 0.004 0.052 0.260
Neutrophils 0.075 0.012 0.017 0.133 0.072 <0.001 0.038 0.107 0.079 <0.001 0.051 0.107
Lymphocytes NS NS NS
Biochemistry
Urea NS 0.041 <0.001 0.022 0.059 0.048 <0.001 0.031 0.065
Uric acid NS 0.002 0.003 0.001 0.004 0.002 0.012 0.001 0.004
Albumins –0.086 0.029 –0.162 –0.009 NS –0.079 0.019 –0.143 –0.015
CRP 0.006 <0.001 0.003 0.008 0.006 <0.001 0.004 0.009 0.008 <0.001 0.006 0.009
Procalcitonin NS 0.786 0.004 0.268 1.303 0.026 0.044 0.001 0.051
Hs-Troponin T NS NS NS
Ratios
N/LyP 0.138 0.003 0.049 0.226 0.149 <0.001 0.072 0.226 0.013 0.042 0.001 0.026
N/Ly 0.059 0.004 0.019 0.098 0.079 <0.001 0.041 0.118 0.026 0.004 0.009 0.043
PNLR 0.0002 0.013 3.47E–
05
0.0003 0.0002 0.001 8.16E–
05
0.0003 0.0003 <0.001 0.0002 0.0005
Ly/CRP NS –1.933 0.045 –3.826 –0.041 –0.776 0.033 –1.487 –0.064
Days of hospitalization –0.018 0.017 –0.032 –0.003
*RC– regression coefficient
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creased susceptibility and poor outcome among elderly 
COVID-19 patients11. Obesity, on the other hand, may ag-
gravate COVID-19 because it might be connected with 
overactive inflammation and immune response, increased 
expression of ACE2, increased abdominal pressure, lim-
ited chest expansion and insufficient respiratory compen-
satory function12. Inhomogeneous bilateral shading was 
typical radiological finding for non-survivors in our sam-
ple, while interestingly about 50 % of patients in each 
group had normal presentation on repeated radiological 
diagnostic imaging methods. According to the data from 
literature, even asymptomatic patients might have pneu-
monia manifested with chest CT imaging abnormalities13. 
Rapid evolution from focal unilateral to diffuse bilateral 
ground-glass opacities that progressed to or co-existed 
with consolidations within 1–3 weeks was typical for coro-
navirus positive patients emphasizing the necessity of 
continuous supervisions13. 
Among laboratory findings, leukocytes and absolute 
lymphocyte counts were greater in OHNS group, as well 
as between survivors and IHNS. After 7 days, we noticed 
an increase in leukocyte and neutrophils counts among 
IHNS. Separately, we analysed patients with and without 
proven bacterial co-infection at the admission, and we no-
ticed a significant difference in complete and differential 
blood count neither at the admission nor after 7 days. Our 
results e, therefore, indicated higher leukocytes and neu-
trophils counts in older COVID-19 positive patients with 
worse outcome unrelated to bacterial infection. According 
to literature, leucocytosis and neutrophilia are observed 
in a minority of COVID-19 infected patients, and they 
mostly follow bacterial superinfection, although neutro-
philia might be also the consequence of the cytokine 
storm, a hyperinflammatory state and it is accompanied 
with severe form of the disease14. In contrary, lymphopenia 
is a typical finding in 35–75% of COVID-19 positive pa-
tients, mostly those with fatal outcome, and it is believed 
it represents a defective immune response to the virus15. 
Researchers have discovered geographic variability in the 
percentage of COVID-19 patients who developed lympho-
penia, e.g. among Chinese more often than in Italian or 
Singapore populations and that might be explain why it 
was not typical in our cohort16,17. Among Chinese popula-
tion leukopenia, lymphocytopenia and eosinophil cytope-
nia are the most typical peripheral blood count findings18. 
C reactive protein, the most common used reactant of 
acute infection, is increased in 75%–93% of patients with 
COVID-19 infection, particularly in severe form of dis-
ease, including viremia19. In our study CRP differed at all 
time points between the three groups, from the highest in 
IHNS to the lowest in S group. At the admission, survivors 
had lower values of lactate dehydrogenase, aspartate 
transaminase, sedimentation ratio and C-reactive protein, 
OHNS were in the middle, and IHNS had the highest 
values. According to the data from literature, high lactate 
dehydrogenase level, serum ferritin, cardiac and muscle 
injury, liver and kidney function, hyperglycaemia and co-
agulation measures seem to be independent predictors of 
in-hospital mortality and more severe forms of infection 
in patients with COVID-1920–22. A meta-analysis in Asian 
population compared laboratory findings between severe 
and non-severe COVID 19 positive patients. The results 
showed a significant decrease in lymphocyte, monocyte, 
and eosinophil, haemoglobin, platelet, albumin, serum 
sodium, lymphocyte to C-reactive protein ratio, and an 
increase in the neutrophil, alanine aminotransferase, as-
TABLE 6
RECOMMENDED CUT-OFF VALUES FOR SIGNIFICANT MARKERS FOR THE PREDICTION OF IN –










Ne1 0.630 0.023 0.486 0.742 ≥3.75 65 64
Leu2 0.760 <0.001 0.621 0.853 ≥8.40 70 84
Ne2 0.798 <0.001 0.672 0.879 ≥5.47 78 70
Leu3 0.729 0.001 0.541 0.848 ≥9.30 71 75
Ne3 0.768 <0.001 0.582 0.878 ≥6.18 71 74
N/LP1 0.631 0.103 0.385 0.793 ≥1.78 82 73
N/LP2 0.714 0.013 0.469 0.856 ≥2.65 75 70
N/LP3 0.788 <0.001 0.553 0.907 ≥2.39 73 85
N/L1 0.686 0.039 0.420 0.843 ≥3.32 69 69
N/L2 0.788 0.002 0.494 0.920 ≥4.14 73 75
N/L3 0.871 <0.001 0.686 0.949 ≥4.08 91 73
PNLR1 0.835 <0.001 0.614 0.934 ≥621.5 64 61
PNLR2 0.719 0.016 0.455 0.867 ≥1600.24 73 73
PNLR3 0.733 0.011 0.466 0.878 ≥1287.9 72 78
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partate aminotransferase, total bilirubin, blood urea ni-
trogen, creatinine, erythrocyte sedimentation rate, C-re-
active protein, procalcitonin, lactate dehydrogenase, 
fibrinogen, prothrombin time, D-dimer, glucose level, and 
neutrophil to lymphocyte ratio in the severe group com-
pared with the non-severe group23. No significant changes 
in white blood cells, creatine kinase, troponin I, myoglo-
bin, IL-6 and K between the two groups were observed23. 
Results of several studies confirmed that increased neu-
trophil to lymphocyte ratio could be an independent pre-
dictor of in-hospital death in Chinese COVID-19 patients, 
while NLR over 4 predicted transfer to intensive care unit 
among Italian patients24–26. In addition to NLR, we showed 
that in our sample higher N/LP and PNLR were also con-
nected to worse outcome. 
In conclusion, in spite of numerous studies published 
in a short period of time willing to elucidate pathophysiol-
ogy, risk factors, outcome, treatment options and all other 
aspects of this novel global threat, we still have a lot of 
doubts. The question arises whether Chinese results can 
be applied globally? Are there differences among different 
populations caused by ethnicity, geographical position or 
genetic variability? Is there the same sort of SARS-CoV2 
in the whole world? In our study we have compared easily 
available clinical and laboratory parameters among south 
Croatian population in recognizing COVID-19 patients at 
higher risk that can be helpful in everyday clinical prac-
tice in implementing increased surveillance among them. 
In the future, novel studies are needed on larger samples, 
especially taking into account the effectiveness of poten-
tial vaccines. COVID-19 pandemic has highlighted the 
urgency of building a global system that can support both 
routine and pandemic adult immunization, as a strategy 
to preserve and improve medical, social, and economic 
outcomes, including maintaining functional ability that 
benefits older adults, their families, and communities27. 
Combined strategy of education and prevention of illness 
with finding effective, but harmless vaccine might be a 
solution for preventing outbreaks in nursing home resi-
dents caused by a variety of infectious agents including 
SARS-CoV28.
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OBILJEŽJA INFEKCIJE COVID-19 MEĐU ŠTIĆENICIMA DOMOVA ZA STARIJE – PRESJEČNA 
STUDIJA IZ HRVATSKE
S A Ž E T A K
S obzirom na visok rizik od smrtnosti povezane s infekcijom zbog oslabljenog imuniteta, stariji pacijenti imaju povećan rizik od 
zaraze COVID-19. U dijagnostičkom postupku klinička laboratorijska medicina ima ključnu ulogu. Cilj ovog istraživanja bio je istraži-
ti kliničke i laboratorijske specifičnosti u hrvatskoj populaciji štićenika domova za starije pogođenih koronavirusom. U ovu retrospektivnu 
studiju uključeno je 106 štićenika domova za starije koji su hospitalizirani zbog infekcije COVID-19. Klinički i laboratorijski nalazi u tri 
vremenska razdoblja izvučeni su iz medicinske evidencije. Istraživanje je uključilo 86 žena i 20 muškaraca, srednje dobi 84 (min. – maks. 
47–97) godine. Pacijenti su podijeljeni u tri skupine: preživjeli (S), pacijenti koji su još uvijek živi (N = 65), (IHNS), pacijenti koji su 
umrli od koronavirusa tijekom hospitalizacije (N = 31) i (OHNS), pacijenti koji su se oporavili od infekcije, ali su umrli tijekom razdoblja 
od tri mjeseca praćenja (N = 10). Utvrdili smo značajne razlike između ove tri skupine u laboratorijskim nalazima (p <0,05). Istraživanje 
pokazuje da procjene kompletne krvne slike, diferencijalne krvne slike, reaktanata akutne infekcije i kombinacija njihovih omjera mogu 
ukazivati na lošiji ishod štićenika domova za starije zbog infekcije koronavirusom.

